Breaking Finance News

NovaBay Pharma (NYSEAMERICAN:NBY) stock price target reduced to $8.00, issued a report earlier today by Laidlaw

Reporting a possible upside of 0.80%, Laidlaw bumped down the target of NovaBay Pharma (NYSEAMERICAN:NBY) to $8.00

Yesterday NovaBay Pharma (NYSEAMERICAN:NBY) traded 3.45% higher at $4.45. NovaBay Pharma’s 50-day moving average is $4.46 and its two hundred day average is $3.81. With the last close up 18.18% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.02% over the date range. Volume of trade was down over the average, with 3,814 shares of NBY changing hands under the typical 14,672

Recent Performance Chart


With a total market value of $0, NovaBay Pharma has with a 52 week low of $2.25 and a 52 week high of $5.09 .

A total of 3 brokers have reported on the stock. 0 brokerages rating the stock a strong buy, 2 brokerages rating the stock a buy, zero equity analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $20.00.

Brief Synopsis About NovaBay Pharma (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.